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Abstract
Background: The Malaria Clinical Trials Alliance (MCTA), a programme of INDEPTH network of demographic 
surveillance centres, was launched in 2006 with two broad objectives: to facilitate the timely development of a 
network of centres in Africa with the capacity to conduct clinical trials of malaria vaccines and drugs under conditions 
of good clinical practice (GCP); and to support, strengthen and mentor the centres in the network to facilitate their 
progression towards self-sustaining clinical research centres.
Case description: Sixteen research centres in 10 African malaria-endemic countries were selected that were already 
working with the Malaria Vaccine Initiative (MVI) or the Medicines for Malaria Venture (MMV). All centres were visited to 
assess their requirements for research capacity development through infrastructure strengthening and training. 
Support provided by MCTA included: laboratory and facility refurbishment; workshops on GCP, malaria diagnosis, 
strategic management and media training; and training to support staff to undertake accreditation examinations of 
the Association of Clinical Research Professionals (ACRP). Short attachments to other network centres were also 
supported to facilitate sharing practices within the Alliance. MCTA also played a key role in the creation of the African 
Media & Malaria Research Network (AMMREN), which aims to promote interaction between researchers and the media 
for appropriate publicity and media reporting of research and developments on malaria, including drug and vaccine 
trials.
Conclusion: In three years, MCTA strengthened 13 centres to perform GCP-compliant drug and vaccine trials, 
including 11 centres that form the backbone of a large phase III malaria vaccine trial. MCTA activities have 
demonstrated that centres can be brought up to GCP compliance on this time scale, but the costs are substantial and 
there is a need for further support of other centres to meet the growing demand for clinical trial capacity. The MCTA 
experience also indicates that capacity development in clinical trials is best carried out in the context of preparation for 
specific trials. In this regard MCTA centres involved in the phase III malaria vaccine trial were, on average, more 
successful at consolidating the training and infrastructure support than those centres focussing only on drug trials.
Background
About one million African children die of malaria each
year [1]. Advances in molecular biology and biotechnol-
ogy have brought an increased focus on the development
of new drugs, vaccines, insecticides and diagnostic tools
that can be deployed to reduce the burden of disease and
ultimately to eradicate malaria. The discovery and devel-
opment of malaria control tools has been promoted
through the formation of several international public-pri-
vate partnerships. These include the Malaria Vaccine Ini-
tiative (MVI), the Medicines for Malaria Venture (MMV),
the European Malaria Vaccine Initiative (EMVI), the
Foundation for Innovative New Diagnostics (FIND), the
African Malaria Network Trust (AMANET), the Drugs
for Neglected Diseases initiative (DNDi) and the institute
for One World Health (iOWH). This has led to the devel-
opment of a relatively rich product development portfolio
over the last two decades. It is essential, however, that the
efficacy and effectiveness of new malaria control tools are
evaluated in the disease endemic areas [2] and there has
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been growing recognition of the urgent need to build and
strengthen human and infrastructure capacity in Africa
to conduct rigorous evaluation trials and studies. This led
to the creation of the Multilateral Initiative on Malaria
(MIM) and, more recently, the European & Developing
Countries Clinical Trials Partnership (EDCTP). However,
with few exceptions, relatively little was done either to
support the refurbishment of the laboratories and clinics
or to develop clinical trial capacity among staff associated
with the trial field sites for intervention studies. Rather
than developing local capacity, there was a tendency to
use external contract research organizations (CROs) to
provide the necessary expertise for trial conduct and rela-
tively little was left behind at a research centre after the
completion of a trial. Typically, CROs secured the rights
to conduct clinical trials, and put African scientists under
intense pressure to meet GCP conditions, only to disap-
pear after recruiting the number of patients necessary for
a specific trial, leaving little behind and creating a situa-
tion where any trained personnel had to move on. This
mode of operation does not support the development of
sustainable infrastructure and expertise for clinical trials.
The development of a regulated and sustained clinical
trials platform has not been given the attention it
deserves in sub-Saharan Africa, despite the urgent pres-
ent and future need to evaluate the tools being developed
to control diseases endemic in the region. There was
insignificant participation in product development by
African scientists and the lack of well-developed clinical
trials platforms in Africa contrasted with the develop-
ment of strong trial centres, not only in developed coun-
tries but also in Asia and Latin America. The regional
disparity in capacity development is exemplified by the
early development and pre-registration studies of various
forms of artemisinin-based combination therapy (ACT)
for malaria. These were mostly undertaken in Asia [3,4]
with only post-registration studies in children conducted
in Africa [5-8]. Consequently, most new anti-malarials
have been deployed in Africa with limited knowledge of
their efficacy and safety in the local population. The clini-
cal trial centres that have been developed in Africa have
generally been strongly linked to northern partners [9]
and local scientists not empowered to engage with indus-
try and other partners involved in product development
in an equitable and effective way. The few sites that have
been developed in this way have tended not to have clini-
cal trials as their primary activity, with little development
of a broader research capacity. Most trial sites have been
based in or linked to health facilities that were purpose
built to provide health care with minimum infrastructure
[10], and were thus not equipped to support GCP compli-
ant clinical trials. Missing were appropriate rooms for
consenting, monitoring, administration of the study
drugs or vaccines and a study participant tracking system.
The relative absence of clinical trial centres in Africa
has had negative impact on the development of careers in
clinical trials for African clinicians and scientists, and on
the development of facilities to conduct GCP and regula-
tory compliant trials in the region. The human capacity
has to be developed to move the clinical trials agenda in
Africa to the next level. There is need for a sustained
framework to strengthen clinical trial research centres in
the sub-Saharan Africa to have a readily available net-
work of centres with the capacity to conduct GCP-com-
pliant clinical trials for the timely evaluation of new
products and interventions. Recognition of this need led
to the birth of Malaria Clinical Trials Alliance (MCTA) as
a programme of the INDEPTH network, to find ways of
establishing and sustaining GCP-compliant trial centres
in Africa to enable the clinical trials capacity in Africa to
begin to match that present in developing countries in
Asia and Latin America.
Case description
Launch of MCTA
The INDEPTH Network was established in 1998 as a net-
work of demographic surveillance sites in developing
countries. One of the early aims was to strengthen the
sites in the network to contribute towards the develop-
ment and evaluation of disease control interventions,
including new drugs and vaccines [11]. After several years
of development within the network a successful grant
application was made to the Bill & Melinda Gates Foun-
dation to support the MCTA, an African-led alliance to
strengthen clinical trials capacity and to promote sharing
of good practices, with activities linked to ongoing and
new clinical trials in malaria. It was set up to take advan-
tage of site-site interactions to share best practices
between centres. This was done by identifying centres
with expertise in particular areas and facilitating sharing
of that expertise with other centres. The main objectives
of MCTA were to facilitate the timely development of a
network of centres in Africa with the capacity to conduct
clinical trials of malaria vaccines and drugs under condi-
tions of GCP; and to support, strengthen and mentor the
centres in the network to facilitate their progression
towards self-sustaining clinical research centres. To
achieve these objectives, MCTA formed strategic part-
nerships with MMV and MVI, the two leading organiza-
tions established to catalyse the development of new anti-
malarial drugs and vaccines respectively. The centres
invited to join the MCTA platform were from among
those previously working with MMV on drug trials and
MVI on vaccine trials. The 16 centres comprising the
MCTA network are shown in Table 1. MCTA site support
focused on strengthening critical capabilities not com-
monly covered by clinical trial budgets, summarized in
Table 2.Ogutu et al. Malaria Journal 2010, 9:103
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Table 1: Clinical trial centres comprising the Malaria Clinical Trials Alliance.
Centre Host Institution Country
Nanoro Mission Hospital Institut, de Recherche en Sciences de la 
Sante/Direction Regionale de I' Ouest
Burkina Faso
Albert Schweitzer Hospital, 
Lambarene
Medical Research Unit, Gabon
Kintampo Health Research Centre Ministry of Health Ghana
Agogo Hospital, Kumasi Centre for 
Collaborative Research
School of Medical Sciences Kwame 
Nkrumah University of Science and 
Technology (KNUST)
Ghana
Kisumu, Kenya Medical Research Institute 
(KEMRI)-Walter Reed Project, Kombewa 
Clinical Trials Unit
Centre for Clinical Research, KEMRI Kenya
Kisumu, KEMRI-Centres for Disease 
Control, Siaya District Hospital Clinical 
Research Centre
Centre for Global Health Research, KEMRI Kenya
KEMRI-Wellcome Trust Programme, Kilifi Centre Geographic Medicine Research, 
KEMRI
Kenya
Ndirande Research Clinic, Ndirande Health 
Centre
Blantyre Malaria Project, affiliate of Malawi 
College of Medicine & University of 
Maryland
Malawi
Lilongwe, Malawi University of North Carolina Project Malawi
Manhiça District Hospital Centro de Investigação em Saúde da 
Manhiça
Mozambique
Ibadan Department of Pharmacology, University 
of Ibadan
Nigeria
State Specialist Hospital, Maiduguri University of Maiduguri Teaching Hospital Nigeria
Bagamoyo Research and Training Centre Ifakara Health Institute Tanzania
Korogwe, Tanga, Tanzania Tanga Centre, National Institute of Medical 
Research
Tanzania
Centre Sur Roi Baudouin Department of Parasitology, Université 
Cheikh Anta Diop
Senegal
Fajara Medical Research Council Laboratories The GambiaOgutu et al. Malaria Journal 2010, 9:103
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Procedures
From its inception MCTA set out to work with partners
already involved in clinical trials capacity development in
Africa, such as AMANET [12] and the Pan-African Bio-
ethics Initiative (PABIN) for GCP and ethics training sup-
port, and the Association of Clinical Research
Professionals (ACRP) East African Chapter for accredita-
tion of clinical trials personnel. MCTA also took advan-
tage of the existing capabilities within some sites and has
facilitated sharing of good practices across the platform.
For example, the centre in Kombewa, Kenya had particu-
lar skills in malaria diagnosis and microscopy and coordi-
nated the external quality assurance, and there was a pool
of trained facilitators supporting the AMANET GCP
training based at the various research institutions in
Africa. The MCTA site capacity strengthening involved
site visits, workshops, inter-site attachment, mentoring,
guided infrastructure refurbishment and linking sites to
new partners. Care was taken to ensure that for every
infrastructure put in place there was expertise to use it
and an output expected.
MCTA also draws on the expertise of a team of eminent
malaria researchers, who have been involved in site
development in Africa, with individual experts linked to
particular centres to provide mentorship to the site lead-
ership through site visits. The mentors also advise the
secretariat on the capacity and the needs of the site.
Governance
MCTA is a programme of the INDEPTH network with an
autonomous Board of Management and a secretariat
operating within the INDEPTH network framework and
statutes. The secretariat is responsible for mobilization of
funds, site visits, managing the grants, site networking,
networking with partners and organizing conferences
and workshops. The Board is the final authority that
oversees the general governance and approves the annual
budget estimates, grants to the sites and guidelines for
MCTA activities.
Achievements
Workshops, attachments, programmes and conferences
MCTA has held an annual scientific meeting, with a spe-
cific theme each year. This meeting brings together site
leaders, mentors and the Board of Management to review
the progress made and plans for the future. In addition
MCTA has supported workshops targeting areas critical
for the conduct of GCP-compliant clinical trials. These
are organised jointly with other partners with expertise in
these areas to maximize resources utilization. The GCP
workshops have been facilitated in collaboration with
AMANET and ACRP [13] and malaria diagnostics by the
KEMRI-WRP Malaria Diagnostic Centre of Excellence
[14]. A summary of the short courses organised to enable
staff to acquire the necessary skills to conduct clinical tri-
als and manage their sites effectively is given in Table 3.
The workshops have all been over-subscribed. The need
for in-depth understanding of GCP principles is made
necessary by new requirements of funding agencies for
GCP certification of Principal Investigators and study
team members.
MCTA supported the launch of the East African chap-
ter of the ACRP, the first in the region which led to the
Table 2: Capacity development activities supported by 
MCTA
Physical Infrastructure
Refurbishment
Refurbishment of clinical 
facilities in hospitals and 
health centres - providing 
room and fittings for 
consenting, out-patient and 
inpatient monitoring 
facilities, radiology and 
pharmacy
Supporting acquisition of 
critical equipment to ensure 
study subject safety and 
study endpoint 
determination - X-ray 
equipment and nursing care 
equipment
Refurbishment of laboratory 
space and purchase of 
equipment for clinical 
chemistry, haematology, 
malaria diagnosis, 
bacteriology, sample 
processing, QC/QA system,
Refurbishment and 
equipping of data 
management infrastructure
Refurbishment and 
equipping clinical trial 
administration infrastructure
Capacity development Site mentorship by senior 
scientists who have been 
involved in site development
Networking of the sites to 
encourage sharing of good 
practices and development 
of collaborations.
Creating visibility of the sites 
in country and the region by 
facilitating media interactionOgutu et al. Malaria Journal 2010, 9:103
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establishment of accreditation exam centre in Nairobi,
Kenya hosted by Strathmore University. Since the incep-
tion of the centre in 2007, MCTA has facilitated the
accreditation of nine certified clinical research coordina-
tors, three certified research auditors, four certified phy-
sician investigators and two GCP facilitators.
MCTA has sponsored four short term cross-site attach-
ments, which have enabled exchange of good practices
between the sites and identification common research
interests, facilitating the formulation of cross site proj-
ects. Five mentors have made visits to seven sites to offer
critical unbiased evaluations of site activities. To help
centres achieve long-term sustainability, MCTA has orga-
nized strategic management workshops facilitated by the
Strathmore Business School, Nairobi, to help site teams
acquire corporate skills and also develop strategic plans.
In order to increase visibility of the centres and narrow
the gap in public knowledge on clinical trials, MCTA sup-
ported the launch of African Media and Malaria Research
Network, coordinated from Accra, Ghana, with local
chapters in all the 10 countries where MCTA is support-
ing sites. This has led to closer collaboration of scientists
at the centres and local media, with several sites develop-
ing documentaries facilitated by the AMMREN country
chapters. Media workshops have been organized to bring
together scientists and journalists from the 10 countries
to exchange knowledge and develop a common agenda to
increase the visibility of malaria research in their coun-
tries. The sites have been assisted in the convening of
media workshops for their local media to facilitate
exchange of ideas and to increase the understanding of
the activities of the centres within the media fraternity.
AMMREN has facilitated the dissemination of the vari-
ous activities at the centres in print media and TV chan-
nels, including the appearance of MCTA scientists in
radio and TV programmes.
MCTA has supported the Malaria Diagnosis Centre of
Ex c e l l e n c e  ( M DC o E )  i n  K i s u m u  t o  se t  u p  a  s i t e - bas ed
malaria microscopy EQA programme that involves
exchange of malaria blood slides between the sites every
quarter to monitor the proficiency of the laboratory tech-
nologists involved in malaria diagnosis. An accreditation
programme for malaria microscopists has also been initi-
ated and so far 28 laboratory personnel have been accred-
ited at basic level and there are plans for advanced level
accreditation. In partnership with MDCoE, MCTA has
also facilitated the setting up of another centre of excel-
lence in malaria diagnosis at Kintampo, Ghana to
increase the number of sites that can offer malaria diag-
nosis retraining to meet the clinical trials demands. A
francophone version the malaria diagnostic training pro-
gramme will be launched in 2010.
Site assessment and refurbishment
The awards of grants for site refurbishment were pre-
ceded by an assessment by teams from MCTA or in part-
nership with MMV and MVI, which identified the needs
and strengths of the sites. This was followed by identifica-
tion of good practices that could be shared across the
Alliance. Some of the good practices included health and
demographic surveillance (HDSS) for site characteriza-
tion and study participant follow-up, management of
severe malaria, data management, malaria diagnosis and
certification of clinical trials professionals. The site visits
revealed substantial disparities in the capacities of differ-
ent centres and even supposedly well-established centres
were found to have deficiencies that required urgent sup-
Table 3: Capacity development workshops organised by MCTA
Activity Attendees (N)
Year 2006 2007 2008 Total
GCP (number of 
workshops (n = 7)
61 51 57 189
GCP Certification 
workshop (n = 1)
02 7 63 3
Malaria diagnosis 
workshops (n = 5)
14 30 29 71
Strategic Management 
Process (n = 2)
02 3 2 5 4 6
Media workshop (n = 2) 21 20 0 44Ogutu et al. Malaria Journal 2010, 9:103
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port to enable them be fully GCP compliant. This
brought to the fore the enormity of the resource needs to
have GCP compliant platform meeting the regulatory
standards. Between 2006 and 2008, grant applications for
capacity strengthening were received from 13 of the 16
MCTA sites and about US$7,300,000 was disbursed for
guided site refurbishment, targeting the specific areas
critical to conduct of clinical trials (Tables 4 and 5). The
difference in amounts is because equipment like X-ray
was secured centrally and some of the requested
resources were not for physical infrastructure support.
The guided infrastructure support has been product
development-driven and was performed in consultation
with MMV and MVI. The guided support focused on
what is critical to the execution of planned activities that
are not likely to be covered by the clinical trial budget.
The support to the centres was critical for the successful
execution of the multi-centre phase III trial of paediatric
dispersible artemether/lumefantrine in children [15] and
several multi-centre and single centre phase II RTSS
malaria vaccine studies [16,17].
The cost of the same equipment varied across countries
and this had implications on the funding across the plat-
form. This may call for centralized procurement, but the
latter may cause problems with service contracts after
installation if local distributors are not involved in the
transaction. In some countries equipment did not attract
customs duty while in others the duty was high, as much
as 50% of the cost of the equipment. In most cases, unless
equipment is purchased through a local distributor, after-
sales service may be problematic. This was evident when
MCTA centrally procured digital X-rays for distribution
to the 11 sites involved in the phase III RTS, S malaria
vaccine study. The shipment of the equipment from Hol-
land to some countries took several months due to lim-
ited flights to some destinations and this was coupled
with lengthy custom clearance processes. In some coun-
tries, there were no local dealers to provide technical sup-
port and reliance on a cross-border technical support
wrought with delays, including going through stringent
immigration procedures occasioning months of delay to
access the site.
The sites conducting malaria drug studies only per-
formed less well over the three years compared to those
conducting malaria vaccines or vaccines/drugs. This was
partly because there were very few new malaria drugs
getting into phase II/III clinical trials compared to
malaria vaccines. The performance was based on site
evaluation assessment tool that focused on administra-
tive structure, physical infrastructure (lab facilities, clini-
cal facilities, data management, research administration)
human resource, site demographic characterization, dis-
ease transmission pattern characterization, specific dis-
ease management policies, clinical trail SOPs, clinical
trial portfolio, collaborations, ongoing projects and
capacity for effective collaboration. The three sites that
did not receive infrastructure support from MCTA dur-
ing the three years due to lack of any ongoing or planned
clinical trials were all malaria drug trial only sites, how-
ever, they participated in staff capacity development
workshops supported by MCTA.
The lessons learned
A summary of the lessons learned in the first three years
of operation of MCTA are summarized in Appendix 1. To
mitigate some of the challenges identified, partners
involved in trial centres as sponsors, collaborators and
CROs should not only focus on the short-term gains from
their trials, but should work to enhance the capacity of
the physical infrastructure, processes and human
resource. The centres must give emphasis to building fis-
cal and legal capacity and systems to enable them negoti-
ate effectively with the partners that need to collaborate
with them or use their facilities for academic research or
product development. This will enable the centres to
leverage resources from the partnerships to support their
core and strategic activities to make them more sustain-
able and competitive. MCTA was a unique programme
that supported the development of physical infrastruc-
Table 4: Grants requested and disbursed for guided infrastructure development.
Year Grants (US$)
Requested Approved
2006 2,655,349 1,500,889
2007 5,067,892 3,184,461
2008 3,185,218.75 1,388,273
Total 10,908,459.75 6,073,623Ogutu et al. Malaria Journal 2010, 9:103
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ture. Most funders shy away from this despite knowing
how critical it is to sound conduct of research, product
development and meeting stringent regulatory standards.
The infrastructure development was tightly linked to the
development of anti-malarial drugs and vaccines. This
ensured that the capacity that was developed was fully
utilised not just for clinical trials but to a large extent in
improving the health of the community around the cen-
tres. The impact on the health of the community is criti-
cal in creating a buy in by the community to feel part of
the research centre for long term community partnership
sustainability. Continued support for clinical trial capac-
ity strengthening is required and can be part of larger ini-
tiatives such as malaria eradication/elimination, HIV/TB
control, and disease surveillance in resource constrained
settings. This continued investment in infrastructure
development for clinical trials remains an essential cata-
lyst to seeing Africa fully participate and ultimately be a
key player in product development.
It is important to note that developing the appropriate
human resource will require as much effort as physical
infrastructure development, as the former drives the lat-
ter. The human capacity required to support clinical trials
is broad (research managers, clinical research coordina-
tors, clinical research auditors, clinical trialists, pharma-
cologists, immunologists, clinical laboratory
technologists, microbiologist, data managers, statisti-
cians, clinical care, epidemiologists & demographers) and
a number are needed for optimal execution of a single
trial. Developing human resources is not just about sup-
porting the centres but also the wider clinical trials frater-
nity, other disease control initiatives and ministries of
health departments. Well-trained clinical trial personnel
are in high demand in the pharmaceutical industry,
CROs, medical NGOs and government agencies leading
to high turn-over. Sustaining the trial centres with mini-
mal human resources is a recipe for disaster and there
must be a concerted effort to plan for staff attrition at all
levels. To stem high attrition rates of the critical clinical
trial personnel, the partners at each centre must devise
innovative ways to keep the staff motivated, such as a
clear career path and competitive and attractive remuner-
ation and staff development packages. Human capacity
strengthening in the malaria endemic areas will remain
crucial to the malaria eradication/elimination agenda to
support product and interventions development and pol-
Table 5: Grants disbursed for specific activities.
Activity Year
Grants (U$)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Clinical area 
refurbishment
214227 (16) 1,215,027 (38) 569850 (22) 1,999,104 (28)
Clinical care 
equipment
40000 (2) 96,870 (3) 49600 (2) 186,470 (3)
Laboratory 
refurbishment
322,636 (24) 289,738 (9) 69414 (3) 681,788 (9)
Laboratory equipment 457405 (34) 935750 (29) 506711 (19) 1,899,866 (27)
Administration 
refurbishment
102700 (8) 409,300 (13) 62626 (2) 574,626 (8)
Administration 
equipment
214228 (16) 237,776 (8) 128064 (5) 580, 067 (8)
X-ray equipment (11 
units)
0 0 1,240,500 (47) 1,240,500 (17)
Total 1,351,195 3,184,461 2,626,765 7,162,421Ogutu et al. Malaria Journal 2010, 9:103
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icy formulation, implementation, monitoring and evalua-
tion. The rich diversity of the clinical team enables the
clinical trial centres at country and regional level to play a
central role in partnership with the academic institutions,
ministry of health departments and NGOs in the health
sector and business schools in facilitating health research
human capacity development and the integration of cor-
porate management leadership skills in healthcare.
Conclusions
The common approach for conducting clinical trials in
resource-poor countries has been to do the minimum site
development required to perform a specific trial, yet gaps
have been identified in the clinical trials capacity. This
has impeded sustainable development and local owner-
ship of the research agenda at sites and has not assisted
their progression to viable research centres. MCTA has,
in a short time, been able to provide the sites in the alli-
ance more flexibility and ownership. This has reduced the
lead time necessary for the execution of clinical trials at
these centres. The current number of trained and quali-
fied clinical trialists and support staff in Africa is still
small and in dire need for expansion, through the provi-
sion of long-term training at graduate, postgraduate and
professional levels. This is an expensive but necessary
venture and must be addressed by all interested partners
on a sustainable basis. Those involved in building a sus-
tainable functional clinical research platform in Africa
should bring on board African governments, private sec-
tor, bilateral and multilateral agencies and philanthropic
foundations. All these partners are stakeholders in the
activities at the research centres in different capacities at
different times. Concerted support will succeed if it is
based on trust and guided by professionals who under-
stand the dynamics of clinical research in resource-poor
settings.
Appendix 1. Lessons learned through the first 3 
years of operation of MCTA
Physical infrastructure
1. Currently available clinical facilities were largely devel-
oped for clinical care and the very few developed for clin-
ical trials were designed for small studies and were not
suitable for medium to large studies (in terms of space for
recruitment, consenting, screening, laboratory evalua-
tions) and had no provision for equipment back up or cal-
ibration, service contracts and QC/QA programmes.
2. It was possible to upgrade capacity at sites with rela-
tively modest levels of funding and less the US $2 million
that been recommended to refurbish a site to perform
clinical trials to GCP standards [9]. The sites have devel-
oped a feeling of ownership as the support has not been
linked to a specific product or partner.
Capacity
1. Linking of capacity strengthening to specific interven-
tion trials at the sites is essential to avoid mismatch with
resultant redundant infrastructure
2. Frequent GCP, GCLP, malaria diagnosis and human
protection training programmes are required due to staff
turn over, expansion, maintenance of accreditation and
also to satisfy regulatory requirements for retraining.
3. There is need for centralized advice on availability,
selection, ordering, installation and post-installation ser-
vice of equipment. However, to ensure optimal acquisi-
tion and maintenance of equipment, the supply of
equipment to the sites was done by the site teams
through local distributors based in country or in a nearby
country. This ensured that there was continued technical
support and supply of specific consumables after installa-
tion. The X-ray machines were the only equipment pro-
cured centrally, but MCTA ensured that there was
regional or in country support post installation.
4. Sharing of information across the network and hav-
ing support readily available to assist other sites in their
areas of competence has been very valuable.
5. The quality of funding requests improved as the site
teams engaged better with the secretariat with a focus on
plans for sustainability
6. There is need for sites to have clear channels of com-
munication with regulatory authorities, independent
review boards and relevant government departments,
whose activities have a direct bearing on the site opera-
tions. Failure to establish these channels can result in
delays in approvals for trial conduct and equipment
acquisition.
7. The long term development and sustainability of
sites/centres will require diversification of their research
portfolio [18] within a specific disease and across dis-
eases. Capacity for research, other than through clinical
trials, needs to be developed as it is unlikely that a site can
be sustained in the long term only through the conduct of
clinical trials.
8. Some of the sites conducting malaria research were
among the first to register a reduction in malaria burden
[19], which exemplifies the indirect benefit of research to
the community by improved bed-net coverage, better
uptake of new intervention strategies i.e. health educa-
tion and effective drugs.
9. The changing transmission dynamics of malaria may
result in some sites becoming unsuitable for evaluating
new malaria interventions, because of a low malaria inci-
dence. However the capacity developed at the sites
should enable them to provide platforms for monitoring
the changing epidemiology and act as sentinel sites for
malaria resurgence. There will be a need to identify and
strengthen new sites in areas with higher disease burden,Ogutu et al. Malaria Journal 2010, 9:103
http://www.malariajournal.com/content/9/1/103
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making site development and sustenance a continuous
process.
10. Even with the capacity development provided
through MCTA, there is limited number of personnel
with expertise in clinical trials across all the sites to meet
the likely demands for evaluating new malaria interven-
tions [18]. A long-term training framework for future
clinical trialists is required to be able to achieve a critical
mass of trialists at the sites and in the region.
Abbreviations
AMANET: African Malaria Network Trust; AMMREN: African Media and Malaria
Research Network; ACRP: Association of Clinical Research Professionals; BoM:
Board of Management; CRC: Clinical Research Coordinator; CCRC: Certified
Clinical Research Coordinator; CDC: Centres for Disease Control & Prevention;
CRA: Clinical Research Associate; CRO: Contract Research Organization; DNDi:
Drugs for Neglected Disease Initiative; EDCTP: European & Developing Coun-
tries Clinical Trials Partnership; EMVI: European Malaria Vaccine Initiative; EQA:
External Quality Assurance Scheme; FIND: Foundation for innovative New
Diagnostics; INDEPTH: International Network for Demographic Evaluation of
Populations and their Health in developing countries; KEMRI: Kenya Medical
Research Institute; HDSS: Health & Demographic Surveillance System; HIV:
Human Immunodeficiency Virus; GCLP: Good Clinical and Laboratory Practice;
GCP: Good Clinical Practice; MCTA: Malaria Clinical Trials Alliance; MDCoE:
Malaria Diagnosis Centre of Excellence; MIM: Multilateral Initiative on Malaria;
MMV: Medicines for Malaria Venture; PABIN: Pan-African Bioethics Initiative;
PATH-MVI- Program for Appropriate Technology in Health-Malaria Vaccination
Initiative; QA: Quality Assurance; QC: Quality Control; TDR: WHO: Tropical Dis-
ease Research program; TB: Tuberculosis; UNC: University of North Carolina,
Chapel Hill; WRP: Walter Reed Project
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BO is the Senior Clinical Trialist with MCTA program; designed and coordinated
the writing of the manuscript, RB is a Clinical Trialist with MCTA; contributed to
the design and writing of the manuscript, DD was a Clinical Trialist with MCTA
and contributed to the writing of the manuscript, PGS is mentor with the
MCTA and contributed to the writing of the manuscript and FNB is the MCTA
Programme Director and had overall oversight on the design and writing of
the manuscript. All the authors reviewed the final manuscript and approved it
before submission.
Acknowledgements
This manuscript has been published with the permission of the executive 
director of the INDEPTH-Network, we are indebted to the site leaders who lead 
the work at site and worked closely with MCTA secretariat. We are grateful to 
MCTA Board of Management who provided oversight of the MCTA activities 
(Dr. Pascoal Mocumbi (Chair), representing MVI (Drs. Dr. Carolyn Petersen & 
Tonya Villafana), Dr Theonest K Mutabingwa (Morogoro MOMS Project, Tanza-
nia), representing MMV (Drs. Lise Riopel & Joerg Moehrle), Dr. Nadia Torn-
ieporth (Sanofi Pasteur) and Ms. Jessica Milman (BMGF), the site mentors, Prof. 
Pedro Alonso, Prof. Brian Greenwood, Prof. Kevin Marsh, Prof. Ogobara 
Doumbo, Prof. Marcel Tanner, Dr. Salim Abdulla, Dr. Seth Owusu-Agyei who 
offered their valuable time to visit the various sites and offered invaluable tech-
nical advice to site leaders and the MCTA secretariat. We acknowledge the 
invaluable support of Raymond Akparibo (MCTA finance officer) and Margaret 
Bugase (MCTA administrative assistant). Financial support: MCTA is funded by 
the Bill & Melinda Gates Foundation grant number 41144.
Author Details
1Malaria Clinical Trials Alliance, INDEPTH Network, 11 Mensah Wood Road, East 
Legon, PO Box KD 213, Kanda, Accra Ghana and 2London School of Hygiene & 
Tropical Medicine, Keppel St, London WC1E 7HT, UK
References
1. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, Stein C, 
Nahlen BL, Bryce J, Black RE, Steketee RW: The burden of malaria 
mortality among African children in the year 2000.  Int J Epidemiol 2006, 
35:691-704.
2. Lang TA, Kokwaro GO: Malaria drug and vaccine trials in Africa: 
obstacles and opportunities.  Trans R Soc Trop Med Hyg 2008, 102:7-10.
3. Nosten F, White NJ: Artemisinin-based combination treatment of 
falciparum malaria.  Am J Trop Med Hyg 2007, 77(6 Suppl):181-192.
4. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the treatment 
of uncomplicated falciparum malaria.  Expert Opin Pharmacother 2007, 
8:75-94.
5. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt 
P, De Palacios PI: Efficacy and safety of the six-dose regimen of 
artemether-lumefantrine in pediatrics with uncomplicated 
Plasmodium falciparum malaria: a pooled analysis of individual patient 
data.  Am J Trop Med Hyg 2006, 74:991-998.
6. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, 
Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, 
Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-
piperaquine for treatment of malaria: a randomized trial.  PLoS Clin Trials 
2007, 2:e20.
7. Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, Croft SL: 
Anti-malarial efficacy of pyronaridine and artesunate in combination 
in vitro and in vivo.  Acta Trop 2008, 105:222-228.
8. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, 
Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna 
S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, 
Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR: Amodiaquine-
artesunate versus amodiaquine for uncomplicated Plasmodium 
falciparum malaria in African children: a randomised, multicentre trial.  
Lancet 2002, 359:1365-1372.
9. Moran M, Guzman J, Ropers A, Jorgensen M, Mcdonald A, Potter S, Haile-
Selassie H: The malaria product pipeline: Managing the trial site 
network, Planning for the future.  2007 [http://
www.thegeorgeinstitute.org]. Health Policy Division, The George Institute 
for International Health. Publication
10. English M, Esamai F, Wasunna A, Were F, Ogutu B, Wamae A, Snow RW, 
Peshu N: Assessment of inpatient paediatric care in first referral level 
hospitals in 13 districts in Kenya.  Lancet 2004, 363:1948-1953.
11. Tatem AJ, Snow RW, Hay SI: Mapping the environmental coverage of the 
INDEPTH demographic surveillance system network in rural Africa.  
Trop Med Int Health 2006, 11:1318-1326.
12. Kilama WL, Chilengi R, Wanga CL: Towards an African-driven malaria 
vaccine development program: history and activities of the African 
Malaria Network Trust (AMANET).  Am J Trop Med Hyg 2007, 77:282-8.
13. Association of Clinical Research Professionals (ACRP):  [http://
www.acrpnet.org].
14. Ohrt C, Obare P, Nanakorn A, Adhiambo C, Awuondo K, O'Meara WP, 
Remich S, Martin K, Cook E, Chretien JP, Lucas C, Osoga J, McEvoy P, 
Owaga ML, Odera JS, Ogutu B: Establishing a malaria diagnostics centre 
of excellence in Kisumu, Kenya.  Malar J 2007, 6:79.
15. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel M, 
Ogutu B, Mårtensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q, Juma 
E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M, Lefèvre G, Ubben 
D, Premji Z: Efficacy and safety of artemether-lumefantrine dispersible 
tablets compared with crushed commercial tablets in African infants 
and children with uncomplicated malaria: a randomised, single-blind, 
multicentre trial.  Lancet 2008, 372:1819-1827.
16. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, 
Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, 
Schellenberg DM, Carter T, Villafana T, Demoitié MA, Dubois MC, Leach A, 
Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M: Safety and 
immunogenicity of RTS, S/AS02D malaria vaccine in infants.  NEJM 
2008, 359:2533-2544.
17. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, 
Lang T, Gould J, Dubois MC, Demoitié MA, Stallaert JF, Vansadia P, Carter T, 
Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, 
Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge 
MM, Marsh K, von Seidlein L: Efficacy of RTS,S/AS01E vaccine against 
malaria in children 5 to 17 months of age.  NEJM 2008, 359:2521-2532. Received: 14 December 2009 Accepted: 20 April 2010 
Published: 20 April 2010
This article is available from: http://www.malariajournal.com/content/9/1/103 © 2010 Ogutu et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Malaria Journal 2010, 9:103Ogutu et al. Malaria Journal 2010, 9:103
http://www.malariajournal.com/content/9/1/103
Page 10 of 10
18. Moran M, Guzman J, Ropers A, Jorgensen M, Mcdonald A, Potter S, Haile-
Selassie H: Managing the trial site network; The malaria product 
pipeline: Planning for the future.  2007 [http://
www.thegeorgeinstitute.org]. Health Policy Division, The George Institute 
for International Health. Publication
19. Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, Marsh K, Snow 
RW: The decline in paediatric malaria admissions on the coast of 
Kenya.  Malar J 2007, 6:151.
doi: 10.1186/1475-2875-9-103
Cite this article as: Ogutu et al., Sustainable development of a GCP-compli-
ant clinical trials platform in Africa: the Malaria Clinical Trials Alliance perspec-
tive Malaria Journal 2010, 9:103